IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer. (Q54346297)

28 May 2018

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer. (English)

1 reference

28 May 2018

cancer-associated fibroblast

main subject

1 reference

1 reference

X Sun

1

1 reference

28 May 2018

Y Mao

2

1 reference

28 May 2018

J Wang

3

1 reference

28 May 2018

L Zu

4

1 reference

28 May 2018

M Hao

5

1 reference

28 May 2018

G Cheng

6

1 reference

28 May 2018

Q Qu

7

1 reference

28 May 2018

D Cui

8

1 reference

28 May 2018

E T Keller

9

1 reference

28 May 2018

X Chen

10

1 reference

28 May 2018

K Shen

11

1 reference

28 May 2018

J Wang

12

1 reference

28 May 2018

language of work or name

English

0 references

publication date

9 June 2014

1 reference

28 May 2018

published in

Oncogene

1 reference

28 May 2018

https://scigraph.springernature.com/pub.10.1038/onc.2014.158

exact match

0 references

cites work

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Mechanisms of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Stromal cells in tumor microenvironment and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Breast stromal fibroblasts from histologically normal surgical margins are pro-carcinogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Structure of the mitotic checkpoint complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Structures of APC/C(Cdh1) with substrates identify Cdh1 and Apc10 as the D-box co-receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Role of STAT3 in Transformation and Drug Resistance in CML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Circulating interleukin-6 predicts survival in patients with metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.158

31 March 2020

Identifiers

DOI

10.1038/ONC.2014.158

1 reference

28 May 2018

PubMed ID

24909173

1 reference

28 May 2018